(Source: MARKETWIRE)

Elsevier Business Intelligence and Windhover Conferences have
announced a major addition to the lineup for their upcoming
Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In
Roche and Genentech: Understanding Their Collaborative Business
Development Model, the two executives who designed and implemented the
radical new collaborative business model will share exactly how they
make this relationship work and the outlook for the business model in
the future.
Mary Graves, Executive Director, Roche Pharma Partnering, and Suzy
Jones, Senior Director of Business Development, Genentech Partnering,
will outline Roche's strategy for retaining Genentech's business
development team despite taking the company private. The executives
will discuss a variety of strategies, including:
-- Early stage, late stage and TAs, and who does what deal
-- Who to talk to about partnering based on asset stage and therapeutic
area
-- Strategic priorities in the merged company
-- Commercializing licensed products after the merger
Therapeutic Area Partnerships will also feature its popular Top 10
Projects to Watch, including a Top 10 in each of four therapeutic
areas: cardiovascular/metabolic, oncology, neuroscience and
inflammatory/autoimmune. According to Roger Longman, Managing
Director, Pharma, of Elsevier Business Intelligence, many companies
previously featured on the Top 10 list have gone on to negotiate major
deals.
The complete list of all projects to date (in random order) is
available at www.windhover.com/taprojects. Each project has been
hand-selected by Windhover's elite selection panel to ensure a
high-quality slate of presenters.
Companies will present the product's target and first indication(s);
other compounds addressing the same target; the relative advantage of
the compound; the clinical results to date and general clinical plan
for the future; IP on the compound or target; and any partnerships
the company currently holds on the compound. Registered attendees
have access to pre-conference access to a database that includes
detailed technical, non-confidential information on projects
available for partnering (pre-clinical and clinical stage).
Industry analysts will open each Top 10 session with therapy
area-specific discussions on Matchmaking in Drug Partnering:
Identifying the Right Drugs and the Right Partners
A major partnering event
Therapeutic Area Partnerships is the industry's most targeted and
efficient partnering meeting for life science companies seeking
partnerships in the top therapeutic areas. Decision-makers (business
development and R&D) focusing on these therapeutic categories can
meet to develop strategic alliances between their companies.